INTRODUCTION
Soft tissue sarcomas (STSs) comprise a highly diverse group of mesenchymal tumors (Ͼ 50 known histologic subtypes) with various natural histories, genetics, prognostic factors, and treatment sensitivities. [1] [2] [3] [4] Tumors may develop at any site, but manifest most often in the extremities and metastasize most often to the lungs and liver. STSs account for 15% of childhood cancers and less than 1% of adult cancers in the United States 5 ; estimated mortality associated with these tumors is high (Ͼ 40%). 6 Prognosis for patients with advanced higher-grade STS is poor: historical median overall survival (OS) is 8 to 12 months after developing metastatic disease. 5 Chemotherapy is the standard treatment for metastatic or unresectable STS. First-line palliative chemotherapy may be beneficial to nearly 50% of patients with advanced STS. 3 Doxorubicin and ifosfamide are considered the most active chemotherapeutic agents, yielding relatively consistent response rates of 10% and 25%, respectively, when administered as monotherapy. 7, 8 Higher response rates were achievedinsomestudiesbyusingcombinationchemotherapy, but multidrug regimens have as yet failed to improve OS when compared with single agents administered sequentially. 8, 9 Moreover, hepatic metabolism of ifosfamide releases its active metabolite, isophosphoramide mustard (IPM) but also releases other metabolites associated with hemorrhagic cystitis, nephrotoxicity, and central neurotoxicity, which can be severe and occasionally fatal. Ifosfamide administration is also complicated because it requires administration of mesna to prevent hemorrhagic cystitis. 10 Tumors often consist of large areas of highly hypoxic microenvironments that are associated with a poor prognosis and increased resistance to chemotherapy and radiotherapy. [11] [12] [13] [14] [15] In human STS, tumor hypoxia is prominent [15] [16] [17] and is associated with shorter survival. 18 Doxorubicin may not adequately penetrate hypoxic regions of solid tumors. 19 We hypothesize that tumor hypoxia may be a meaningful therapeutic target in patients with STS.
TH-302 (Threshold Pharmaceuticals, South San Francisco, CA, and Merck, Darmstatdt, Germany) is a hypoxia-activated nitroimidazole prodrug of the cytotoxic alkylating agent bromoisophosphoramide mustard (Br-IPM). TH-302 is reduced at its nitroimidazole site by intracellular reductases and, under hypoxic conditions, it releases Br-IPM, the active metabolite. Br-IPM acts as a DNA cross-linking agent, rendering cells unable to replicate and divide. Findings from preclinical studies have also demonstrated a bystander effect of TH-302, which is likely associated with diffusion of the active moiety to adjacent normoxic regions of the tumor and possibly provides additional antitumor activity. 20 Because TH-302 is preferentially activated in hypoxic tissues and does not have the same toxic metabolites (eg, acrolein and chloroacetaldehyde) as ifosfamide following hepatic metabolism, TH-302 should hypothetically display fewer hematologic, renal, bladder, and CNS toxicities than ifosfamide. This hypothesis could be supported by the specific reversible skin and mucosal toxicities found to be dose limiting in a phase I study of TH-302. 21 A phase I/II trial of TH-302 in combination with doxorubicin in patients with advanced STS was conducted. The maximum-tolerated dose (MTD) of TH-302 was established at 300 mg/m 2 when combined with full-dose doxorubicin (75 mg/m 2 ) and prophylactic growth factor support (granulocyte colony-stimulating factor). 22 Here, we present the results for the phase II trial of the combination therapy in first-line treatment of patients with advanced STS dosed at the MTD.
PATIENTS AND METHODS

Study Population
Patients (age Ն 18 years) had locally advanced unresectable or metastatic, intermediate-or high-grade STS for which no standard curative therapy was available and for which single-agent doxorubicin was considered appropriate treatment. No central pathology review was conducted. Patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; at least one target lesion evaluable by RECIST 1.0 23 ; and adequate hepatic, renal, hematologic, and cardiac function. Patients who had received prior systemic therapy other than neoadjuvant or adjuvant therapy were excluded. Complete criteria are available in Ganjoo et al 22 and the Appendix (online only). The study protocol was approved by the institutional review board for each study site, and all patients provided written informed consent for their participation.
Study Design
The primary objective of the single-arm, multicenter phase II segment of this open-label study was to perform a preliminary assessment of the efficacy of TH-302, administered at the MTD (300 mg/m 2 ) established in the phase I segment, when combined with doxorubicin in patients with advanced STS. The study population included all patients enrolled and treated in the phase II (dose expansion) segment, as well as six patients treated at the MTD in the phase I dose-escalation segment who met the dose expansion eligibility criteria. No stopping rules were incorporated. The primary efficacy outcome measure was progression-free survival (PFS) rate at 6 months, in accordance with the suggestion of Van Glabbeke et al 24 for phase II trials in STS. Six-month PFS rates between 30% and 56% have been reported for first-line chemotherapy, depending on STS histologic subtype. 24 RECIST response rates of 10% to 25% have also been reported in first-line chemotherapy. These rates were used as a standard to assess the observed efficacy. A posteriori, the sample size enabled the PFS rate at 6 months to be estimated with an SE of 5%.
TH-302 was administered by intravenous infusion over 30 minutes on days 1 and 8 of a 21-day cycle. The dose of doxorubicin was fixed at 75 mg/m 2 (56 mg/m 2 if bilirubin was higher than the upper limit of normal but Յ 1.5ϫ upper limit of normal) and was administered by bolus injection on day 1 of a 21-day cycle for up to six cycles (maximum cumulative dose, 450 mg/m 2 ). Dexrazoxane (Zinecard; Pharmacia and Upjohn, New York, NY) was permitted at the discretion of the treating physician and used in only four patients. On days when both TH-302 and doxorubicin were administered, doxorubicin was injected 2 hours after completion of the TH-302 infusion. The Appendix contains information on dose modifications followed for hematologic, liver, and renal toxicities regardless of causality and for any other toxicity that was not clearly related to disease progression, intercurrent illness, concomitant medications, or other nondrug intervention (Appendix Tables A1-A3, online only). Prophylactic growth factor support (filgrastim or pegfilgrastim) was given from day 8 or 9 of cycles but could be discontinued at the investigator's discretion if neutropenia was minimal after the first two cycles. Prophylaxis against nausea and vomiting was implemented by using a regimen intended for moderately emetogenic chemotherapy. After six cycles, patients who had stable disease (SD) or responding disease after completing the combination therapy could continue on TH-302 monotherapy (maintenance) on days 1 and 8 of a 21-day cycle until disease progression or discontinuation for another reason.
Assessments and Outcome Measures
No patient was replaced, and analyses include all patients with available data. Tumor response was evaluated by the clinical site radiologist and medical oncologist after every even cycle using RECIST 1.0. SD required a minimum duration of 6 weeks. Survival follow-up continued for as long as 36 months. Efficacy outcome measures were PFS, best response, and confirmed response (requiring subsequent assessment at least 4 weeks after initial assessment of response) rates, duration of response, OS, and ECOG PS. PFS and OS end points, including rates at points in time, medians, and survival curves, were estimated by using the Kaplan-Meier method and associated 95% CIs. PFS included all deaths occurring within 9 weeks of the last tumor response assessment and all deaths occurring within 6 months of treatment initiation if not preceded by documented disease progression. Univariable and multivariable models were performed to compare PFS and OS across subgroups. The logrank test was used to compare subgroups in the univariable models, and a stepwise Cox regression model was used for the multivariable analyses. The following covariates were analyzed: sex (male, female), age (Ն 60 years, Ͻ 60 years), ECOG PS (0, 1), metastatic disease (yes, no), time from initial diagnosis (Յ 1 year, Ͼ 1 year), time from advanced/metastatic disease (Յ 3 months, Ͼ 3 months), sites of disease (Յ four, Ͼ four), leiomyosarcoma (yes, no), liposarcoma (yes, no), unclassified and/or malignant fibrous histiocytoma (MFH; yes, no), site of primary (extremity, other), maximum tumor diameter (Յ 5 cm, Ͼ 5 cm), prior radiotherapy (yes, no), albumin (Ͻ 3.5 g/dL, Ն 3.5 g/dL), and hemoglobin (Ͻ 12 g/dL, Ն 12 g/dL). For the Cox model, the significant level to enter the model was 0.15, and the level to stay was 0.05; sex and age were fixed factors.
Clinical laboratory test results collected weekly, vital signs collected on dosing days, weight, and adverse events (AEs) were used to assess safety and/or tolerability and were summarized by using descriptive statistics. Severity of AEs or clinically significant laboratory test results were graded by using the Common Terminology Criteria for Adverse Events version 3.0.
RESULTS
Between August 2009 and June 2011, 91 patients received induction therapy with doxorubicin combined with the MTD of TH-302. Of these 91, 59 patients (65%) received six cycles of combination therapy, and 48 patients (53%) later received maintenance therapy with TH-302 alone. Baseline demographic and disease characteristics of the patients are summarized in Table 1 . Of the 91 patients, 34 (37%) were age 60 years or older. The most common histopathologic diagnoses were leiomyosarcoma (31%), unclassified sarcoma and/or MFH (31%), and liposarcoma (21%). Most patients (82% on induction; 88% on maintenance) had distant metastases, particularly to the lung (69% on induction; 71% on maintenance). Approximately one fifth of patients had liver metastases (18% on induction; 21% on maintenance), including 9% with both liver and lung metastases. The median maximum tumor diameter was 6.1 cm, and 57% of patients had a target lesion larger than 5 cm in diameter.
Median drug exposure was seven cycles (range, one to 36 cycles). Median follow-up period was 19.4 months (range, 1.0 to 37.7 months). The 48 patients who continued on TH-302 maintenance had a median of 10 total cycles of TH-302 (range, seven to 36 cycles). Overall, 34% of patients had a dose delay and 41% had a dose modification, but this did not affect the overall dose intensity. Median dose intensity for induction therapy was 92% for TH-302 and 94% for doxorubicin.
Efficacy
Six-month PFS (primary efficacy measure) was 58% (95% CI, 46% to 68%), and 3-month PFS was 83% (95% CI, 74% to 89%). Median PFS was 6.5 months (95% CI, 5.8 to 7.7 months). The Kaplan-Meier curve for PFS is presented in Figure 1A . Median PFS after initiating maintenance (n ϭ 48) was 3.7 months (95% CI, 2.4 to 5.5 
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†Other: chondrosarcoma (n ϭ 3). Phase II Trial of Hypoxia-Activated Prodrug TH-302 in STS www.jco.org months), as presented in Figure 1B . There were no significant differences in PFS among subgroups based on univariable (Table 2) or multivariable analyses. For example, the 6-month PFS rates were 65% for leiomyosarcoma, 51% for unclassified and/or MFH, 47% for liposarcoma, and 75% for other subtypes.
Overall, there were two complete responses (CRs) and 30 partial responses (PRs), for an overall response rate of 36%, and confirmed responses were reported for 27 patients (30%). For the 32 patients whose best response was a PR or a CR, the median duration of response was 5.3 months (95% CI, 3.5 to 6.7 months) and ranged from 1.2 to 15.3 months. Forty-four patients (49%) had SD for at least 6 weeks. Response rates were similar across subgroups, except in patients with locally advanced unresectable tumors who had a 13% response rate (n ϭ 16) compared with 41% in patients with distant metastases (n ϭ 75; Table 2 ). The two CRs were reported in patients with angiosarcoma and unclassified undifferentiated sarcoma. Both patients progressed at the next visit at a new disease site. Among the 48 patients who received TH-302 maintenance therapy, the overall response rate was 44% after the combination therapy induction, increasing to 54% after maintenance (ie, including both induction and maintenance). During maintenance, five patients with SD during induction converted to a PR, and one patient with a PR during induction converted to a CR. Figure 1C provides the Kaplan-Meier curve for OS. Median OS was 21.5 months (95% CI, 16.0 to 26.2 months). One-and 2-year survival rates were 73% (95% CI, 63% to 81%) and 44% (95% CI, 33% to 54%), respectively. In multivariable analyses, patients with leiomyosarcoma, higher levels of serum albumin, locally advanced disease, and fewer sites of disease had significantly longer survival. Figure 2 presents the case of a 65-year-old woman with metastatic uterine leiomyosarcoma. She presented with large peritoneal metastases (including a 28-cm mass) with ascites. Comparison of computed tomography scans at baseline and at the end of four cycles of doxorubicin plus TH-302 showed resolution of ascites and a more than 40% decrease in the sum of longest diameters. Further reduction allowed complete resection.
Safety
Hematologic toxicity is summarized by grade (Table 3) . Grade 3 or 4 neutropenia occurred in 28 patients (31%). Febrile neutropenia was rare, occurring in seven patients (8%), with no study discontinuations. Two cases of sepsis were reported with one case associated with grade 4 neutropenia. Grade 3 or 4 thrombocytopenia occurred in 29 patients (32%). Nine patients (10%) received at least one platelet transfusion. There were no thrombocytopenic-associated bleeding events and/or associated discontinuations. However, seven patients discontinued 4.4 to 6.5 months after initiating therapy when platelets did not recover to above 100,000/L by the time requirement for initiating a dosing cycle. Grade 3 or 4 anemia occurred in 33 patients (36%). Seventeen patients (19%) received growth factors for anemia and no patients discontinued as a result of anemia. Grade 3 or 4 hematologic toxicity was seen primarily during induction. Nonhematologic AEs are summarized in Table 4 . Two AEs (subdural hemorrhage and postprocedural hemorrhage) were fatal. A total of 37 patients (41%) experienced 61 serious AEs (SAEs) regardless of relationship to study drug, primarily for hospitalization or prolongation of hospitalization. SAEs occurring in at least three patients were febrile neutropenia (7%), abdominal pain (4%), and fever (3%). Twenty-one SAEs (34% of all reported SAEs) in 17 patients were considered treatment related, including febrile neutropenia (6%) and fever (3%).
The most common nonhematologic AEs initiating in TH-302 maintenance, regardless of relationship to study drug, were pain in extremities (25%), skin rash (21%), diarrhea (21%), fatigue (17%), constipation (17%), and stomatitis (17%). Five patients had a grade 3 AE assessed by the clinical investigator as at least possibly related to TH-302 after initiating maintenance: pruritus and urticaria (two patients), plantar erythema (one), hypoalbuminemia (one), and hypokalemia (one). There were single reports of grade 3 to 4 thrombocytopenia and neutropenia and no reports of grade 3 to 4 leukopenia. One patient was reported with bone marrow hypoplasia after 25 cycles.
No study drug-related deaths occurred during induction or maintenance therapy. There was no evidence of hepatic, renal, or cardiac toxicity related to TH-302 and no other consistent pattern of nonhematologic laboratory abnormalities.
Grade 3 decreases in left ventricular ejection fractions were reported in three patients. One patient had a subsequent assessment in the normal range. The other two decreases were at the last ejection fraction assessment after completing doxorubicin and were considered to be related to doxorubicin.
Seventy-one patients (78%) went on to receive subsequent chemotherapy after discontinuing from the study. The most common chemotherapies were gemcitabine-containing regimens (38%), dacarbazine-containing regimens (21%), or pazopanib-containing regimens (20%). Thirteen (14%) and 16 patients (18%) received a doxorubicin-containing or ifosfamide-containing regimen, respectively. Twenty-two patients (24%) received subsequent radiotherapy.
DISCUSSION
There is an unmet need for a therapeutic agent that can increase the efficacy of first-line doxorubicin treatment of advanced STS without adding unacceptable toxicity. This phase II study used investigatorassessed 6-month PFS rate as the primary variable to assess efficacy of TH-302 administered in combination with doxorubicin in patients who had unresectable localized or metastatic STS and had not previously received first-line systemic chemotherapy. The 6-month PFS rate was 58%, which is higher than historical rates of 30% to 56% reported for first-line chemotherapy for advanced STS. 24 Historically, patients with STS who receive first-line treatment with single-agent doxorubicin survive for a median of 8 to 12 months. To date, results of randomized trials of combination chemotherapy have failed to demonstrate a benefit over single-agent doxorubicin, including the findings from the two most recently reported phase III trials that compared doxorubicin with combination therapy with ifosfamide 25 or palifosfamide. 26 In this single-arm study, postprogression survival was prolonged, with a median OS of 21.5 months, which was 15 months longer than the median PFS. Prolonged survival can be associated with lower-grade tumors. In this study, only five patients were enrolled with sarcomas generally considered to be low grade: four patients with chondrosarcoma and one patient with chordoma. All other patients met eligibility criteria excluding low-grade tumors, but no central pathology review was conducted. Subsequent therapies after discontinuing TH-302 could also have contributed to the observed prolonged survival. After discontinuing TH-302, most patients received subsequent chemotherapy; some patients received doxorubicin and/or ifosfamide. Pazopanib was recently approved for extended PFS but did not show a significant survival benefit. No other therapy has been approved as second-line therapy for non-GI stromal tumor STS.
Implementation of maintenance treatment to prolong response duration and delay disease progression in patients with STS who responded to their first-line chemotherapy regimen is being investigated with various anticancer agents. 5 The data from this study indicate that continued administration of TH-302 as single-agent maintenance therapy is tolerated with limited hematologic toxicity, manageable skin and mucosal toxicity, no cardiac toxicity (a concern with doxorubicin), and no cumulative toxicity. Improved tumor response classifications were observed in six patients during maintenance, and the median PFS after maintenance initiation was 3.7 months. We hypothesize that therapeutic targeting of hypoxic regions of tumors may prolong survival. Hypoxic areas of tumors are believed to serve as sanctuaries for neoplastic cells by shielding them from cytotoxic effects of many conventional chemotherapies. 27-29 TH-302 may suppress or eliminate cells sheltered in these hypoxic areas, such that subsequent disease progression may represent progression in nonhypoxic areas in which conventional cytotoxic salvage therapies may be more effective. Hypoxia may also influence metastatic dissemination of tumor cells from the primary site. 30 TH-302 treatment in the maintenance setting may prevent further metastatic dissemination of cells, thereby delaying development of additional metastatic sites.
Given the association of tumor hypoxia with chemotherapy/ radiation resistance, metastasis, and poor clinical outcomes, the targeting of hypoxic tumor cells is an important and active area of cancer research. Our preliminary efficacy and safety data with a TH-302 hypoxia-targeting strategy in this phase II study supported the initiation of a randomized, controlled phase III study of doxorubicin and TH-302 in STS (NCT01440088). prodrug: a drug that is given in an inactive form and is bioactivated to a pharmacologic drug by one or more metabolic processes.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Dose Modifications
Blood for CBC and serum creatinine was drawn within 5 days of cycle 1 day 1, within 3 days before day 1 of subsequent cycles, and within 1 day of dosing on day 8 of all cycles. Dose modification rules were followed for all hematologic, liver, and renal toxicities regardless of causality and for any other toxicity that was not clearly related to disease progression, intercurrent illness, concomitant medications, or other nondrug intervention. • If a patient required more than two dose reductions for toxicity, he or she discontinued from the study • Any patient who missed more than one cycle (Ͼ 3 weeks of day 1 of a cycle) for treatment-related toxicity discontinued from the study
TH-302 Plus Doxorubicin Dose Modifications
If day 1 of a cycle for either drug was withheld, the whole cycle was delayed. If day 8 was withheld, the dose was skipped rather than delayed.
If study drug was held at day 1 of any cycle, counts were repeated weekly, and therapy was reinstituted when the ANC was Ն 1,500/L and platelets were Ն 100,000/L.
For febrile neutropenia, defined as ANC less than 500/L and temperature Ն 38.2°C (100.8°F), doxorubicin was reduced 25%, and TH-302 was reduced one dose level in all subsequent cycles. 
